{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:31:33Z","timestamp":1784752293982,"version":"3.55.0"},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Psoriasis is a common inflammatory skin condition with an estimated prevalence of 1.5% in the UK. Its management has evolved rapidly over the past 15 years as our understanding of its pathogenesis has progressed. Treatment initiation often overlaps with peak reproductive years, posing specific therapeutic challenges for individuals hoping to conceive. Certain systemic agents are well established to be teratogenic during pregnancy, such as methotrexate and acitretin, but data on newer drug classes for psoriasis remain limited. This literature review evaluated recent data on the systemic agents for psoriasis, explicitly considering the context of male and female fertility, pregnancy and breastfeeding. Our goal was to equip clinicians with an accessible, concise summary of up-to-date evidence to help them educate patients and facilitate informed, shared decision-making aligned with their reproductive health.<\/jats:p>","DOI":"10.1093\/ced\/llae209","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T03:45:32Z","timestamp":1716263132000},"page":"1316-1329","source":"Crossref","is-referenced-by-count":4,"title":["A guide to prescribing systemic treatments for psoriasis during pregnancy, breastfeeding and in those trying to conceive: what does the current evidence suggest?"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6693-8275","authenticated-orcid":false,"given":"Eliza","family":"Hutchison","sequence":"first","affiliation":[{"name":"University Hospitals Bristol and Weston NHS Foundation Trust ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Eraifej","sequence":"additional","affiliation":[{"name":"Aneurin Bevan University Health Board ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Moss","sequence":"additional","affiliation":[{"name":"Gloucestershire Hospitals NHS Foundation Trust ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4139-7193","authenticated-orcid":false,"given":"Sophie","family":"Rolls","sequence":"additional","affiliation":[{"name":"University Hospitals Bristol and Weston NHS Foundation Trust ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4521-2907","authenticated-orcid":false,"given":"Hannah","family":"Wainman","sequence":"additional","affiliation":[{"name":"University Hospitals Bristol and Weston NHS Foundation Trust ,","place":["UK"]},{"name":"University of Bristol , Bristol ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"2024102416194723600_llae209-B1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: a brief overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin Med"},{"key":"2024102416194723600_llae209-B2","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2024102416194723600_llae209-B3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijwd.2019.04.021","article-title":"Clinical considerations for the management of psoriasis in women","volume":"5","author":"Gottlieb","year":"2019","journal-title":"Int J Womens Dermatol"},{"key":"2024102416194723600_llae209-B4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/IJWH.S125784","article-title":"Pustular psoriasis of pregnancy: current perspectives","volume":"10","author":"Trivedi","year":"2018","journal-title":"Int J Womens Health"},{"key":"2024102416194723600_llae209-B5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/1744666X.2022.2008240","article-title":"TYK2 inhibition: changing the treatment landscape for psoriasis?","volume":"18","author":"Abduelmula","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"2024102416194723600_llae209-B6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/qjmed\/92.10.551","article-title":"The effects of methotrexate on pregnancy, fertility and lactation","volume":"92","author":"Lloyd","year":"1999","journal-title":"QJM"},{"key":"2024102416194723600_llae209-B7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000246811","article-title":"Teratogenic risk with etretinate and acitretin treatment","volume":"189","author":"Geiger","year":"1994","journal-title":"Dermatology"},{"key":"2024102416194723600_llae209-B8","doi-asserted-by":"crossref","first-page":"821","DOI":"10.5114\/ada.2020.102089","article-title":"The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines","volume":"37","author":"Owczarek","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"2024102416194723600_llae209-B9","article-title":"Management of pustular psoriasis during pregnancy: is the use of cyclosporine a real solution?","author":"Magdoud","year":"2019"},{"key":"2024102416194723600_llae209-B10","article-title":"Unintended pregnancy during treatment with methotrexate and etanercept for psoriasis \u2013 case report","author":"Gon\u00e7alves","year":"2019"},{"key":"2024102416194723600_llae209-B11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024102416194723600_llae209-B12","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1136\/annrheumdis-2017-211384","article-title":"Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study","volume":"76","author":"Clowse","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024102416194723600_llae209-B13","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3390\/medicina58060780","article-title":"Oversight and management of women with psoriasis in childbearing age","volume":"58","author":"Bucur","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"2024102416194723600_llae209-B14","first-page":"80","article-title":"Treatment algorithms for special cases","volume":"56","author":"Ba\u015fkan","year":"2022","journal-title":"Turkderm \u2013 Turk Arch Dermatol Venereol"},{"key":"2024102416194723600_llae209-B15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40257-022-00698-9","article-title":"Generalized pustular psoriasis in pregnancy: current and future treatments","volume":"23","author":"Seishima","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2024102416194723600_llae209-B16","article-title":"Prednisolone summary of product characteristics","author":"European Medicines Agency","year":"2021"},{"key":"2024102416194723600_llae209-B17","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa071152","article-title":"Outcomes at 2 years of age after repeat doses of antenatal corticosteroids","volume":"357","author":"Crowther","year":"2007","journal-title":"N Engl J Med"},{"key":"2024102416194723600_llae209-B18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ad.2020.10.002","article-title":"Management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding: a consensus statement","volume":"112","author":"Belinch\u00f3n","year":"2021","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"2024102416194723600_llae209-B19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.23736\/S0392-0488.20.06748-6","article-title":"Psoriasis and its management in women of childbearing age: Tools to increase awareness in dermatologists and patients","volume":"155","author":"De Simone","year":"2020","journal-title":"G Ital Dermatol Venereol"},{"key":"2024102416194723600_llae209-B20","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2019-11-6","article-title":"Management of psoriasis in pregnancy \u2013 a review of the evidence to date","volume":"9","author":"Ferreira","year":"2020","journal-title":"Drugs Context"},{"key":"2024102416194723600_llae209-B21","doi-asserted-by":"crossref","first-page":"e13243","DOI":"10.1111\/dth.13243","article-title":"Practical compendium for psoriasis management","volume":"33","author":"Ibrahim","year":"2020","journal-title":"Dermatol Ther"},{"key":"2024102416194723600_llae209-B22","article-title":"Methoxsalen summary of product characteristics","author":"European Medicines Agency","year":"2019"},{"key":"2024102416194723600_llae209-B23","first-page":"653","article-title":"Therapy of psoriasis during pregnancy and breast-feeding","volume":"20","author":"Balakirski","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"2024102416194723600_llae209-B24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.12788\/cutis.0103","article-title":"Treatment of psoriasis in pregnancy","volume":"106","author":"Flood","year":"2020","journal-title":"Cutis"},{"key":"2024102416194723600_llae209-B25","article-title":"Acitretin summary of product characteristics","author":"European Medicines Agency","year":"2024"},{"key":"2024102416194723600_llae209-B26","first-page":"1654","article-title":"Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1)","volume":"34","author":"Lambert","year":"2020","journal-title":"JEADV"},{"key":"2024102416194723600_llae209-B27","first-page":"281","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris \u2013 Part 2: specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"JEADV"},{"key":"2024102416194723600_llae209-B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23736\/S2784-8671.21.07132-2","article-title":"Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis","volume":"157","author":"Gisondi","year":"2022","journal-title":"Ital J Dermatol Venereol"},{"key":"2024102416194723600_llae209-B29","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/humupd\/dmaa022","article-title":"The effect of paternal exposure to immunosuppressive drugs on sexual function, reproductive hormones, fertility, pregnancy and offspring outcomes: a systematic review","volume":"26","author":"Perez-Garcia","year":"2020","journal-title":"Hum Reprod Update"},{"key":"2024102416194723600_llae209-B30","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/17512433.2021.1925536","article-title":"Biologics and small molecules in the management of psoriatic arthritis: reproduction related issues in female and male patients","volume":"14","author":"Fischer-Betz","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2024102416194723600_llae209-B31","article-title":"Otelza summary of product characteristics","author":"European Medicines Agency","year":"2021"},{"key":"2024102416194723600_llae209-B32","doi-asserted-by":"crossref","first-page":"350","DOI":"10.23736\/S2724-6507.20.03236-8","article-title":"Impact of current antipsoriatic systemic treatments on male and female fertility: what endocrinologists need to know","volume":"46","author":"Cacciapuoti","year":"2021","journal-title":"Minerva Endocrinol"},{"key":"2024102416194723600_llae209-B33","article-title":"Skilarence summary of product characteristics","author":"European Medicines Agency","year":"2022"},{"key":"2024102416194723600_llae209-B34","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/medicina57080804","article-title":"State-of-the-art review of pregnancy-related psoriasis","volume":"57","author":"Simionescu","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"2024102416194723600_llae209-B35","volume-title":"Risk of serious infections in offspring exposed in utero to ustekinumab or vedolizumab. Dissertation","author":"Gorodensky","year":"2021"},{"key":"2024102416194723600_llae209-B36","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1177\/1203475420928376","article-title":"Management of plaque psoriasis with biologic therapies in women of child-bearing potential consensus paper","volume":"24","author":"Yeung","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"2024102416194723600_llae209-B37","article-title":"Methotrexate summary of product characteristics","author":"European Medicines Agency","year":"2022"},{"key":"2024102416194723600_llae209-B38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000251036","article-title":"Studies on human semen in topical corticosteroid-treated and in methotrexate-treated psoriatics","volume":"154","author":"Grunnet","year":"1977","journal-title":"Dermatology"},{"key":"2024102416194723600_llae209-B39","article-title":"Capimune summary of product characteristics","author":"European Medicines Agency","year":"2024"},{"key":"2024102416194723600_llae209-B40","first-page":"E2","article-title":"Treatment of generalized pustular psoriasis of pregnancy with infliximab","volume":"107","author":"Beksac","year":"2021","journal-title":"Cutis"},{"key":"2024102416194723600_llae209-B41","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/acr.24813","article-title":"Ustekinumab safety in pregnancy: a comprehensive review","volume":"75","author":"Gorodensky","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024102416194723600_llae209-B42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","article-title":"Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2024102416194723600_llae209-B43","article-title":"Benepali summary of product characteristics","author":"European Medicines Agency","year":"2024"},{"key":"2024102416194723600_llae209-B44","article-title":"Amgevita summary of product characteristics","author":"European Medicines Agency","year":"2023"},{"key":"2024102416194723600_llae209-B45","article-title":"Flixabi summary of product characteristics","author":"European Medicines Agency","year":"2023"},{"key":"2024102416194723600_llae209-B46","article-title":"Simponi summary of product characteristics","author":"European Medicines Agency","year":"2024"},{"key":"2024102416194723600_llae209-B47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.MIB.0000164023.10848.c4","article-title":"Infliximab and semen quality in men with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"2024102416194723600_llae209-B48","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/ced.14263","article-title":"A retrospective review of pregnancies on biologics for the treatment of dermatological conditions","volume":"45","author":"Boggs","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"2024102416194723600_llae209-B49","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/09546634.2020.1750551","article-title":"Secukinumab during pregnancy: a case report and review of literature","volume":"33","author":"Gallo","year":"2022","journal-title":"J Dermatol Treat"},{"key":"2024102416194723600_llae209-B50","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13555-020-00373-z","article-title":"Treatment of psoriasis with secukinumab in challenging patient scenarios: a review of\u00a0the\u00a0available evidence","volume":"10","author":"Wu","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024102416194723600_llae209-B51","article-title":"Cosentyx summary of product characteristics","author":"European Medicines Agency","year":"2023"},{"key":"2024102416194723600_llae209-B52","article-title":"Taltz summary of product characteristics","author":"European Medicines Agency","year":"2023"},{"key":"2024102416194723600_llae209-B53","first-page":"e468","article-title":"Biological therapy in psoriatic patients whishing fatherhood: a multi-centre italian experience in real life","volume":"34","author":"Filippi","year":"2020","journal-title":"JEADV"},{"key":"2024102416194723600_llae209-B54","article-title":"Kynatheum summary of product characteristics","author":"European Medicines Agency","year":"2022"},{"key":"2024102416194723600_llae209-B55","article-title":"Skyrizi summary of product characteristics","author":"European Medicines Agency","year":"2024"},{"key":"2024102416194723600_llae209-B56","article-title":"Ilumetri summary of product characteristics","author":"European Medicines Agency","year":"2023"},{"key":"2024102416194723600_llae209-B57","article-title":"Tremfya summary of product characteristics","author":"European Medicines Agency","year":"2024"},{"key":"2024102416194723600_llae209-B58","first-page":"e14420","article-title":"Use of biologic therapies for psoriasis during pregnancy and long-term outcomes of exposed children: a 14-year real-life experience at a tertiary center in Turkey and review of the literature","volume":"33","author":"Kobaner","year":"2020","journal-title":"Dermatol Ther"},{"key":"2024102416194723600_llae209-B59","article-title":"Stelara summary of product characteristics","author":"European Medicines Agency","year":"2024"},{"key":"2024102416194723600_llae209-B60","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/apt.16960","article-title":"Pregnancy outcomes following periconceptional or gestational exposure to\u00a0ustekinumab: review of cases reported to the manufacturer\u2019s\u00a0global safety database","volume":"56","author":"Mahadevan","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2024102416194723600_llae209-B61","article-title":"Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs","author":"National Institute for Health and Care Excellence"},{"key":"2024102416194723600_llae209-B62","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf"},{"key":"2024102416194723600_llae209-B63","doi-asserted-by":"crossref","first-page":"1759720X19899296","DOI":"10.1177\/1759720X19899296","article-title":"Baricitinib exposure during pregnancy in rheumatoid arthritis","volume":"12","author":"Costanzo","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024102416194723600_llae209-B64","article-title":"Olumiant summary of product characteristics","author":"European Medicines Agency","year":"2024"},{"key":"2024102416194723600_llae209-B65","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2024102416194723600_llae209-B66","article-title":"Deucravacitinib for treating moderate to severe plaque psoriasis","author":"National Institute for Health and Care Excellence"},{"key":"2024102416194723600_llae209-B67","article-title":"Sotyktu summary of product characteristics","author":"European Medicines Agency","year":"2024"},{"key":"2024102416194723600_llae209-B68","article-title":"Contraindications and special considerations: the green book","author":"UK Health Security Agency"},{"key":"2024102416194723600_llae209-B69","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jamadermatol.2023.1400","article-title":"Fertility trends and adverse pregnancy outcomes in female patients with psoriasis in the UK","volume":"159","author":"Chen","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2024102416194723600_llae209-B70","doi-asserted-by":"crossref","first-page":"102676","DOI":"10.1016\/j.jaut.2021.102676","article-title":"Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-\u03b1 during pregnancy: a systemic review and meta-analysis","volume":"122","author":"Barenbrug","year":"2021","journal-title":"J Autoimmun"},{"key":"2024102416194723600_llae209-B71","first-page":"127","article-title":"Fetal acrania (Exencephaly) in the context of a pregnant female taking adalimumab for psoriasis: a case report","volume":"14","author":"Daham","year":"2020","journal-title":"Biologics"},{"key":"2024102416194723600_llae209-B72","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1080\/09546634.2021.1976375","article-title":"Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab","volume":"33","author":"Egeberg","year":"2022","journal-title":"J Dermatol Treat"},{"key":"2024102416194723600_llae209-B73","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.3390\/jcm10245894","article-title":"Impact of psoriasis and hidradenitis suppurativa in pregnancy, a systematic review","volume":"10","author":"Ferrer-Alcala","year":"2021","journal-title":"J Clin Med"},{"key":"2024102416194723600_llae209-B74","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/14712598.2022.1988566","article-title":"Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations","volume":"22","author":"Galluzzo","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"2024102416194723600_llae209-B75","doi-asserted-by":"crossref","first-page":"e15878","DOI":"10.1111\/dth.15878","article-title":"Generalized pustular psoriasis recurring during pregnancy and lactation successfully treated with ixekizumab","volume":"35","author":"Huang","year":"2022","journal-title":"Dermatol Ther"},{"key":"2024102416194723600_llae209-B76","doi-asserted-by":"crossref","first-page":"adv00251","DOI":"10.2340\/00015555-3611","article-title":"Successful treatment of recurrent pustular psoriasis of pregnancy with secukinumab: a case report","volume":"100","author":"Liu","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2024102416194723600_llae209-B77","doi-asserted-by":"crossref","first-page":"e14931","DOI":"10.1111\/dth.14931","article-title":"Considerations on inhibition of IL-23 in psoriatic women of childbearing potential","volume":"34","author":"Russo","year":"2021","journal-title":"Dermatol Ther"},{"key":"2024102416194723600_llae209-B78","doi-asserted-by":"crossref","first-page":"119","DOI":"10.25251\/skin.4.2.4","article-title":"Psoriasis in pregnancy: a review","volume":"4","author":"Shihab","year":"2020","journal-title":"Skin"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae209\/58879192\/llae209.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/11\/1316\/60035539\/llae209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/11\/1316\/60035539\/llae209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T16:20:12Z","timestamp":1729786812000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/11\/1316\/7676846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":78,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,5,21]]},"published-print":{"date-parts":[[2024,10,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae209","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,5,21]]}}}